Adenovirus containing mutations in E1B and E1A selectively targets abnormalities in the p53 or Rb pathways of tumor cells. It redirects GB cells with low coxsackievirus and adenovirus receptor expression by modifying them with RGD or EGFR. The in vivo anti-tumor effect is mainly due to oncolysis and changes in the GB microenvironment influenced by T cells and macrophages. This evidence concerns the gene EGFR and neoplasm.